Myeloma Minute: 7th Annual IMWG Summit


World's Top Myeloma Experts in Copenhagen for 7th Annual IMWG Summit

This week, the International Myeloma Foundation (IMF) hosted the 7th Annual International Myeloma Working Group (IMWG) Summit in Copenhagen, Denmark. One hundred of the world’s top myeloma experts attended the 2016 Summit. Discussions and presentations focused on screening for MGUS, the role of MRD detection in myeloma, transplant in the era of novel therapies and the establishment of IMWG guidelines to address the rising cost of myeloma drugs. Please click HERE for photos from the 2016 Summit, and stay tuned for a report on the highlights by IMF Chairman Dr. Brian Durie in next week’s Myeloma Minute.


The IMF Honors Dr. S. Vincent Rajkumar with the 2016 Robert A. Kyle Lifetime Achievement Award

On June 8th, IMF Chairman Dr. Brian Durie and IMF President Susie Novis Durie presented the 14th Annual Robert A. Lifetime Achievement Award to Dr. S. Vincent Rajkumar. The Edward W. and Betty Knight Scripps Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, Dr. Rajkumar has worked closely with Dr. Kyle for 20 years. Dr. Rajkumar said receiving the Kyle Award “is the highest honor possible for me and I am thankful to the IMF, the IMWG, and my colleagues from around the world.” To read more, click HERE.


IMF Team at ASCO 2016 Films Insightful Overviews of Top Myeloma News

Once again, the IMF team at ASCO 2016 filmed insightful overviews of top myeloma news by the leading myeloma experts at the annual meeting of the American Society of Clinical Oncology in Chicago last week. Dr. Paul Richardson (Dana Farber Cancer Institute) said that the results of the CASTOR study bode ““very well for the future of monoclonal antibodies with both proteasome inhibitors and immunomodulatory drugs, and is going to translate into additional benefit for our patients.” Also in attendance in ASCO was Dr. Sagar Lonial (Winship Cancer Institute), who commented that recent studies of lenalidomide (Revlimid) show shorter responses after relapse, but “there is a significant survival benefit associated with lenalidomide maintenance.” Perhaps the most uplifting commentary on the research studies presented at ASCO 2016 was by Dr. Morie Gertz (Mayo Clinic), who said, “These reports are making it ever-increasingly clear that we are moving toward a cure for multiple myeloma.” Watch all IMF Videos from ASCO 2016 HERE.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.